Founded in 2018 and based in Albuquerque, New Mexico, TNeuroPharma focuses on developing therapeutic-based technology targeting T-cell contributions to track and treat neurodegenerative diseases. The company's core mission is to enable early detection and treatment of Alzheimer's disease through innovative T-cell technology. Their primary product, the T-Track Biomarker, uses blood samples to identify dysfunctional T-cells, allowing for early diagnosis and intervention, which can prevent further complications and improve patient outcomes.
TNeuroPharma has garnered attention for its cutting-edge approach to Alzheimer's detection. While specific notable affiliated people and investors are not mentioned, the company's impact is significant in the field of neurodegenerative disease research. By providing a method for early detection, TNeuroPharma aims to revolutionize how Alzheimer's is diagnosed and treated, potentially altering the disease's trajectory and improving the quality of life for countless patients.
